Search Results

There are 28963 results for: content related to: Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

  1. Managing Postmenopausal Women with Hormone Receptor–Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway

    The Breast Journal

    Volume 20, Issue 4, July/August 2014, Pages: 347–357, Adam M. Brufsky

    Version of Record online : 26 MAY 2014, DOI: 10.1111/tbj.12278

  2. Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 56, Issue 7, July 2016, Pages: 875–884, Shanly M. Chen, Daniel H. Atchley, Michael A. Murphy, Bill J. Gurley and Landry K. Kamdem

    Version of Record online : 31 DEC 2015, DOI: 10.1002/jcph.673

  3. A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma

    Journal of Mass Spectrometry

    Volume 44, Issue 6, June 2009, Pages: 920–928, Giuseppe Corona, Caterina Elia, Bruno Casetta, Crivellari Diana, Sara Rosalen, Mario Bari and Giuseppe Toffoli

    Version of Record online : 12 FEB 2009, DOI: 10.1002/jms.1566

  4. You have free access to this content
    Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma


    Volume 91, Issue 3, 1 February 2001, Pages: 484–489, Bruce E. Hillner and Davide Radice

    Version of Record online : 29 JAN 2001, DOI: 10.1002/1097-0142(20010201)91:3<484::AID-CNCR1026>3.0.CO;2-D

  5. Phase 3 Trials of Aromatase Inhibitors for Breast Cancer Prevention

    Annals of the New York Academy of Sciences

    Volume 1155, Issue 1, February 2009, Pages: 141–161, Barbara K. Dunn and Anne Ryan

    Version of Record online : 26 FEB 2009, DOI: 10.1111/j.1749-6632.2009.03688.x

  6. You have free access to this content
    Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer


    Volume 118, Issue 1, 1 January 2012, Pages: 241–247, Antonio Llombart-Cussac, Amparo Ruiz, Antonio Antón, Agustí Barnadas, Silvia Antolín, José E. Alés-Martínez, Isabel Álvarez, Raquel Andrés, José A. García Saenz, Juan Lao, Eva Carrasco, Carmen Cámara, Isabel Casas and Miguel Martín

    Version of Record online : 29 JUN 2011, DOI: 10.1002/cncr.26299

  7. You have free access to this content
    The therapeutic potential of mTOR inhibitors in breast cancer

    British Journal of Clinical Pharmacology

    Volume 82, Issue 5, November 2016, Pages: 1189–1212, Linda S. Steelman, Alberto M. Martelli, Lucio Cocco, Massimo Libra, Ferdinando Nicoletti, Stephen L. Abrams and James A. McCubrey

    Version of Record online : 10 MAY 2016, DOI: 10.1111/bcp.12958

  8. When to start an aromatase inhibitor: Now or later?

    Journal of Surgical Oncology

    Volume 103, Issue 7, 1 June 2011, Pages: 730–738, Julie C. Doughty

    Version of Record online : 24 FEB 2011, DOI: 10.1002/jso.21801

  9. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery

    Journal of Pharmaceutical Sciences

    Volume 100, Issue 8, August 2011, Pages: 3208–3222, Raju Jukanti, Sruthi Sheela, Suresh Bandari and Prabhakar R. Veerareddy

    Version of Record online : 14 MAR 2011, DOI: 10.1002/jps.22542

  10. MalPEFinder: fast and retrospective assessment of data breaches in malware attacks

    Security and Communication Networks

    Volume 5, Issue 8, August 2012, Pages: 899–915, Shun-Te Liu and Yi-Ming Chen

    Version of Record online : 4 NOV 2011, DOI: 10.1002/sec.390

  11. You have full text access to this OnlineOpen article
    The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer

    International Journal of Clinical Practice

    Volume 61, Issue 12, December 2007, Pages: 2051–2063, C. J. Fabian

    Version of Record online : 24 SEP 2007, DOI: 10.1111/j.1742-1241.2007.01587.x

  12. You have free access to this content
    Landmark trials in endocrine adjuvant therapy for breast carcinoma


    Volume 106, Issue 5, 1 March 2006, Pages: 975–981, William Gradishar

    Version of Record online : 24 JAN 2006, DOI: 10.1002/cncr.21707

  13. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 2, February 2014, Pages: 170–178, A. Gastaldelli, B. Balas, R. Ratner, J. Rosenstock, B. Charbonnel, G. B. Bolli, M. Boldrin and R. Balena

    Version of Record online : 22 AUG 2013, DOI: 10.1111/dom.12192

  14. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

    Intervention Review

    The Cochrane Library

    Lorna Gibson, David Lawrence, Claire Dawson and Judith Bliss

    Published Online : 7 OCT 2009, DOI: 10.1002/14651858.CD003370.pub3

  15. Identifying cutoff scores for the EORTC QLQ-C30 and the head and neck cancer–specific module EORTC QLQ-H&N35 representing unmet supportive care needs in patients with head and neck cancer

    Head & Neck

    Volume 38, Issue S1, April 2016, Pages: E1493–E1500, Femke Jansen, Claire F. Snyder, C. René Leemans and Irma M. Verdonck–de Leeuw

    Version of Record online : 13 NOV 2015, DOI: 10.1002/hed.24266

  16. Cooperating to Commercialize Technology: A Dynamic Model of Fairness Perceptions, Experience, and Cooperation

    Production and Operations Management

    Volume 22, Issue 6, November/December 2013, Pages: 1336–1355, Elco van Burg and Kim E. van Oorschot

    Version of Record online : 11 MAR 2012, DOI: 10.1111/j.1937-5956.2012.01331.x

  17. You have free access to this content
    Exemestane is effective for the chemoprevention of breast cancer

    CA: A Cancer Journal for Clinicians

    Volume 61, Issue 6, November/December 2011, Pages: 363–364, Mary Kay Barton

    Version of Record online : 6 SEP 2011, DOI: 10.3322/caac.20131

  18. Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 5, May 2011, Pages: 596–598, S Santoro, M Santini, CA Pepe, E Tognetti, C Cortelazzi, E Ficarelli and G De Panfilis

    Version of Record online : 20 JUL 2010, DOI: 10.1111/j.1468-3083.2010.03803.x

  19. Determination of plasma levels of exemestane (FCE 24304), a new irreversible aromatase inhibitor, using liquid chromatography/thermospray mass spectrometry

    Journal of Mass Spectrometry

    Volume 30, Issue 5, May 1995, Pages: 693–697, C. Allievi, P. Zugnoni, M. Strolin Benedetti and P. Dostert

    Version of Record online : 14 APR 2005, DOI: 10.1002/jms.1190300506

  20. Secure and transparent network traffic replay, redirect, and relay in a dynamic malware analysis environment

    Security and Communication Networks

    Volume 7, Issue 3, March 2014, Pages: 626–640, Ying-Dar Lin, Tzung-Bi Shih, Yu-Sung Wu and Yuan-Cheng Lai

    Version of Record online : 21 MAR 2013, DOI: 10.1002/sec.764